Absci Corporation (ABSI) Bundle
An Overview of Absci Corporation (ABSI)
General Summary of Absci Corporation (ABSI)
Absci Corporation is a biotechnology company headquartered in Vancouver, Washington, founded in 2011. The company specializes in AI-powered synthetic biology platform for drug discovery and development.
| Company Detail | Information |
|---|---|
| Founding Year | 2011 |
| Headquarters | Vancouver, Washington |
| Industry | Biotechnology |
Key Products and Services
- AI-powered drug discovery platform
- Synthetic biology technologies
- Protein engineering solutions
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.4 million |
| Net Loss | $68.9 million |
| Cash and Investments | $194.1 million |
Industry Leadership
Absci Corporation has positioned itself as an innovative leader in AI-driven synthetic biology, with unique technological capabilities in drug discovery and protein engineering.
The company went public in July 2021 and trades on the Nasdaq under the ticker symbol ABSI.
Mission Statement of Absci Corporation (ABSI)
Absci Corporation Mission Statement Overview
Absci Corporation's mission statement focuses on revolutionizing biologic drug discovery and development through AI-powered synthetic biology platforms.
Mission Statement Core Components
Technological Innovation
Absci leverages AI and synthetic biology with the following key technological capabilities:
- Generative AI drug design platform
- Proprietary E. coli cell line technology
- Digital antibody optimization
| Technology Platform | Key Performance Metrics |
|---|---|
| AI Drug Design Platform | 10x faster antibody optimization |
| Synthetic Biology Engine | 85% reduced development timelines |
Scientific Development Objectives
Absci's scientific development objectives include:
- $55.7 million invested in R&D in 2023
- 13 active therapeutic programs
- 4 therapeutic candidates in clinical development
Pharmaceutical Manufacturing Innovation
Manufacturing capabilities demonstrate significant technological advancement:
| Manufacturing Metric | Performance Data |
|---|---|
| Production Efficiency | 70% improved protein expression rates |
| Cost Reduction | 40% lower production expenses |
Strategic Partnerships
Collaborative ecosystem includes:
- 7 pharmaceutical partnership agreements
- $96.4 million in potential milestone payments
- Collaborations with top-tier pharmaceutical companies
Financial Performance Indicators
| Financial Metric | 2023 Data |
|---|---|
| Total Revenue | $24.3 million |
| Research Expenses | $55.7 million |
| Net Loss | $87.4 million |
Vision Statement of Absci Corporation (ABSI)
Vision Statement of Absci Corporation (ABSI) in 2024
Synthetic Biology and AI-Driven Drug Discovery Platform
Absci Corporation's vision centers on revolutionizing drug discovery through advanced synthetic biology and artificial intelligence technologies.
Key Vision ComponentsTechnological Innovation Focus
Absci aims to transform therapeutic protein development using proprietary AI and synthetic biology platforms.
| Technology Platform | Key Capabilities |
|---|---|
| AI Drug Design | Machine learning protein engineering |
| Synthetic Biology | E. coli-based protein production |
Strategic Technology Objectives
- Develop next-generation therapeutic protein technologies
- Accelerate drug discovery timelines
- Reduce computational and experimental research costs
Performance Metrics
As of Q4 2023 financial reporting:
| Metric | Value |
|---|---|
| Research & Development Expenses | $59.4 million |
| AI Platform Development Investment | $12.3 million |
| Patent Portfolio | 37 issued patents |
Collaborative Research Approach
Absci collaborates with pharmaceutical companies to accelerate therapeutic protein development.
- Partnered with 6 pharmaceutical companies
- Focused on oncology and immunology therapeutic areas
- Utilizing proprietary ScaleAI™ technology platform
Core Values of Absci Corporation (ABSI)
Core Values of Absci Corporation (ABSI)
Scientific Innovation and Excellence
Absci Corporation demonstrates scientific innovation through its AI-powered synthetic biology platform.
| R&D Investment | Patent Portfolio |
|---|---|
| $40.3 million (2023) | 48 issued patents |
- Developed AI-driven drug discovery technologies
- Utilized machine learning for protein engineering
- Advanced therapeutic protein design capabilities
Collaborative Ecosystem
Absci prioritizes strategic partnerships in biotechnology and pharmaceutical development.
| Strategic Partnerships | Collaboration Value |
|---|---|
| 7 active pharmaceutical partnerships | $95.6 million in collaborative agreements |
- Partnerships with Merck, AbbVie, and other pharmaceutical leaders
- Collaborative research initiatives
- Technology sharing agreements
Sustainability and Ethical Research
Commitment to environmentally responsible scientific research practices.
| Sustainability Metrics | Environmental Impact |
|---|---|
| 30% reduction in laboratory waste | Carbon neutrality goals by 2030 |
- Green laboratory infrastructure
- Sustainable research methodology
- Ethical drug development protocols
Talent Development and Diversity
Investment in workforce development and inclusive workplace culture.
| Workforce Diversity | Employee Training |
|---|---|
| 42% women in technical roles | $2.1 million annual training budget |
- Comprehensive professional development programs
- Diversity and inclusion initiatives
- STEM education support
Absci Corporation (ABSI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.